Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 168   

Articles published

VRX 23.13 -0.36 (-1.53%)
price chart
What Can Investors Expect From Valeant Pharmaceuticals Intl Inc.?
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to confound investors, leaving them confused as to whether they should start buying shares, sell their positions, or just not think about it.
Valeant Pharmaceuticals Intl Inc (VRX): A Bull And Bear Duke It Out  ValueWalk
Can Valeant Pharmaceuticals Intl Inc (VRX) Hit Three For Three Tomorrow?  Insider Monkey (blog)
Valeant Pharmaceuticals International Inc reassures investors Mike Pearson ...
BloombergFormer Valeant CEO Michael Pearson, who was replaced by Joseph Papa in May, still holds more than 3.5 million shares and is required to hold 1 million shares for two years following employment termination.
Valeant Pharmaceuticals Intl Inc(NYSE:VRX): Should Investors Short The Stock?  TCC
Biotech Daily Digest: Analysts Chime In on Valeant Pharmaceuticals Intl Inc ...  Smarter Analyst
How Valeant Pharmaceuticals Intl Inc. Could Become a Great Investment
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to drop to new lows. The former darling of the market has seen the stock price plummet over 90% from nearly $350 to a low of just under $26 over the past year.
Valeant Pharmaceuticals Intl Inc (VRX) Calls Hot After Drug, Walgreens News  Schaeffers Research (blog)
Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Second Published Phase 3 Trial ...  TCC
Rodman & Renshaw Bullish on Valeant Pharmaceuticals Intl Inc (VRX) Despite FDA ...
Following what is “clearly a disappointing setback in a month that to date had proved to be one of positive surprises for the company,” Rodman & Renshaw analyst Raghuram Selvaraju reiterates a Buy rating on shares of Valeant Pharmaceuticals Intl Inc ...
Micron Technology, Inc. (NASDAQ:MU) & Valeant Pharmaceuticals Intl (NYSE ...  Money News (press release)
Analyst's Notable Buzzers: Valeant Pharmaceuticals International, Inc ...  Street Updates
Why one FDA snag is moving Valeant Pharmaceuticals investors more than two ...
Even when the majority of news about Valeant Pharmaceuticals International Inc. is good, this week showed that investor confidence in the company remains shaky, and can be easily rattled by even minor setbacks.
Stock Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Receives Complete ...  Smarter Analyst
Valeant Pharmaceuticals International, Inc (VRX): FDA Letter Outlines ...  TCC
Biotech Daily Digest: Valeant Pharmaceuticals Intl Inc (VRX) and Relypsa Inc ...
New insights emerge in the biotech sector as Valeant Pharmaceuticals Intl Inc (NYSE:VRX) received a Complete Response Letter (CRL) from the FDA on its eye drug Vesneo, and Relypsa Inc (NASDAQ:RLYP) agreed to be acquired by Galenica for $32 per ...
Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its ...
LAVAL, Quebec, July 28, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the Board of Directors has appointed Ms. Sarah B. Kavanagh to serve as a director of the Board, effective July 22, ...
Popular Stock: Valeant Pharmaceuticals International, Inc.'s (VRX)  Is stories
Up-To-Date Stocks Report: Valeant Pharmaceuticals International, Inc. (NYSE ...  WsNews 4investors
Valeant Pharmaceuticals Intl Inc (VRX): Bill Ackman's Take on Left's New Short
Bill Ackman, the CEO and founder of Pershing Square Capital, discussed his views on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in an extensive interview with CNBC on Thursday.
Analysts watching two Stocks: Valeant Pharmaceuticals International, Inc ...
Valeant Pharmaceuticals International, Inc.'s (VRX) EPS growth ratio for the past five years was 4.40% while Sales growth for the past five years was 54.60%.
Valeant Pharmaceuticals Intl Inc (VRX) Brodalumab License Revoked for Europe
Valeant Pharmaceuticals Intl. Inc. (NYSE:VRX) announced today that AstraZeneca plc (ADR) (NYSE:AZN) has terminated its license to develop Brodalumab, a plaque psoriasis drug, in Europe.
Stock Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Announces New ...  Smarter Analyst
AstraZeneca plc (ADR) and Valeant Pharmaceuticals Intl Inc (VRX) Ended ...  Business Finance News